fixed dose combination [Bioanalytics]

posted by avinash – India, 2015-03-06 12:18 (4129 d 14:52 ago) – Posting: # 14551
Views: 7,775

Dear Members,

Please let me know, If a fixed dose combination is administered during clinical phase of BA/BE study, where in, different methods are used for analysis; is it sufficient to check the specificity of the analyte in presence of other drug administered along with long term stability, or should a complete method validation is required with the analyte of interest in presence of other FDC drug in QC samples.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
120 visitors (0 registered, 120 guests [including 14 identified bots]).
Forum time: 04:11 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5